Image

Global Glomerular Disease Therapeutics Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Glomerular Disease Therapeutics Market, By Indication (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Glomerular Disease Therapeutics Market

Glomerular Disease Therapeutics Market Analysis and Size

The global glomerular disease therapeutics market is expected to witness significant growth during the forecast period. The growth of glomerular disease therapeutics market is enhanced by the rise in cases of kidney disorder worldwide and vulnerable aging population. Furthermore, ongoing research activities related to glomerular disease therapeutics, high patient awareness level and favourable regulatory scenario are considered as positive indicator for the growth of glomerular disease therapeutics drugs

Data Bridge Market Research analyses a growth rate in the global glomerular disease therapeutics market in the forecast period 2022-2029. The expected CAGR of global glomerular disease therapeutics market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 12590.4 million in 2021, and it would grow upto USD 18,601.7 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Glomerular Disease Therapeutics Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Indication (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral)), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Alkem Labs Ltd (India), Apotex Inc (Canada), WOCKHARDT (India)

Market Opportunities

  • Increased Drug Approvals
  • Increasing Demand for Retail Pharmacies

Market Definition

Glomerular disease is type of renal disorder affecting the small filtering unit of kidneys called glomeruli. It is caused by several factors such as autoimmune disorders, genetic factors, infection in other parts of the body and sclerotic diseases.  

Global Glomerular Disease Therapeutics Market Dynamics

Drivers

  • Increased Incidence of Kidney Diseases

The rising prevalence of chronic kidney disease worldwide is majorly responsible for boosting the growth of the global renal drugs market. According to the National Kidney Foundation reports, approximately 10% of the global population is affected by chronic kidney disease (CKD). Thus, it boosts the market growth.

  • Rising Demand for Oral Drugs

Oral drugs is projected to boost the market growth. The segment is anticipated to increase the global market as majority of the products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increasing Demand for Retail Pharmacies

The rise in the number of renal drugs delivered through retail pharmacies and the increase in the number of retail pharmacies in extremely developed countries create opportunities for the market growth. Additinally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Side Effects of Renal Drugs

The side effects associated with these glomerular disease therapeutics could curb the growth of the global renal drugs market over a forecast period. Effects such as loss of appetite, fever, rashes, can hamper the market growth.

  • High Cost

The huge expenditure associated with these agents hamper the market growth. Several corticosteroids, ACE inhibitors, immunosuppressive therapy types are the ones that are hampering the growth of the market.

This global glomerular disease therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global glomerular disease therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Glomerular Disease Therapeutics Market Scope

The global glomerular disease therapeutics market is segmented on the basis of indication, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Glomerulonephritis
  • Nephropathy
  • Goodpasture Syndrome
  • Others

Treatment

  • Corticosteroids
  • Aristocort
  • Bubbli-Pred
  • Celestone
  • ACE Inhibitors
  • Benazepril
  • Captopril
  • Enalapril
  • Immunosuppressive Therapy
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Glomerular Disease Therapeutics Market Regional Analysis/Insights

The global glomerular disease therapeutics market is analyzed and market size insights and trends are provided by indication, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global glomerular disease therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for global glomerular disease therapeutics market throughout the forecasted period due to increased smoking, hypertension & diabetic population, and presence of key manufacture of the prod to the high diagnostic rate and presence of key players in this region.

North America dominates the market due to the growing cases of kidney disorder, presence of sophisticated medical facilities in order to maximize the treatment effectiveness for patient suffering from glomerular disease and increases focuses in the research and development activity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Glomerular Disease Therapeutics Market Share Analysis

The global glomerular disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global glomerular disease therapeutics market.

Key players operating in the global glomerular disease therapeutics market include:

  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • AbbVie.Inc (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Ltd (India)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Cipla Inc (India)
  • Aurobindo Pharma (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • A Alkem Labs Ltd (India)
  • Apotex Inc (Canada)
  • WOCKHARDT (India)


SKU-
Why Choose Us


Frequently Asked Questions

The global glomerular disease therapeutics market was USD 12590.4 million in 2021.
The global glomerular disease therapeutics market is projected to grow at a CAGR of 5% during the forecast period of 2022-2029.
North America dominates the market due to the growing cases of kidney disorder, the presence of sophisticated medical facilities in order to maximize the treatment effectiveness for a patient suffering from glomerular disease, and increased focus on research and development activity.
Asia-Pacific has been witnessing the highest growth for the global glomerular disease therapeutics market throughout the forecasted period due to increased smoking, hypertension & diabetic population, and the presence of key manufacturers of the prod to the high diagnostic rate and presence of key players in this region.